[Urgent] Starlink Set For The Largest IPO In History?

He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000! And now, Elon could be set to do it for the third and final time… with what might be his biggest breakthrough yet. And for the first time ever, you have the rare chance to profit BEFORE the upcoming IPO.

Click here now for the urgent details on this hidden play.

Pad Chivukula Biography and Net Worth

COO of Arcturus Therapeutics

Dr. Pad Chivukula is the Chief Scientific Officer and Chief Operating Officer of Arcturus Therapeutics. Dr. Chivukula has an exceptional and technically solid foundation in nanoparticle technology. Prior to Arcturus, from 2008 until February 2013, Dr. Chivukula was employed by Nitto, where his titles included Group Leader and Chief Scientist. Dr. Chivukula brings over 15 years of experience in drug delivery and therapeutic drug development, including leading the polymeric RNAi research department at Nitto. Dr. Chivukula has a Ph.D. in Pharmaceutical Chemistry from the University of Utah where he specialized in nanoparticle technology.

What is Pad Chivukula's net worth?: The estimated net worth of Pad Chivukula is at least $6.97 million as of October 15th, 2024. Dr. Chivukula owns 435,334 shares of Arcturus Therapeutics stock worth more than $6,974,051 as of November 15th. This net worth approximation does not reflect any other assets that Dr. Chivukula may own. Additionally, Dr. Chivukula receives an annual salary of $687,500.00 as COO at Arcturus Therapeutics. Learn More about Pad Chivukula's net worth.
How old is Pad Chivukula?: Dr. Chivukula is currently 45 years old. There are 3 older executives and no younger executives at Arcturus Therapeutics. The oldest executive at Arcturus Therapeutics is Dr. Juergen Froehlich FCPh, M.D., MBA, Chief Medical Officer, who is 68 years old. Learn More on Pad Chivukula's age.
What is Pad Chivukula's salary?: As the COO of Arcturus Therapeutics Holdings Inc., Dr. Chivukula earns $687,500.00 per year. The highest earning executive at Arcturus Therapeutics is Mr. Joseph E. Payne M.Sc., Founder, President, CEO & Director, who commands a salary of $906,500.00 per year. Learn More on Pad Chivukula's salary.
How do I contact Pad Chivukula?: The corporate mailing address for Dr. Chivukula and other Arcturus Therapeutics executives is 10628 SCIENCE CENTER DRIVE SUITE 200, SAN DIEGO CA, 92121. Arcturus Therapeutics can also be reached via phone at (858) 900-2660 and via email at [email protected]. Learn More on Pad Chivukula's contact information.
Has Pad Chivukula been buying or selling shares of Arcturus Therapeutics?: During the last ninety days, Pad Chivukula has sold $249,120.00 in shares of Arcturus Therapeutics stock. Most recently, Pad Chivukula sold 12,000 shares of the business's stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $20.76, for a transaction totalling $249,120.00. Following the completion of the sale, the chief operating officer now directly owns 435,334 shares of the company's stock, valued at $9,037,533.84. Learn More on Pad Chivukula's trading history.
Are insiders buying or selling shares of Arcturus Therapeutics?: During the last twelve months, insiders at the biotechnology company sold shares 5 times. They sold a total of 64,114 shares worth more than $2,204,944.35. The most recent insider tranaction occured on October, 15th when COO Pad Chivukula sold 12,000 shares worth more than $249,120.00. Insiders at Arcturus Therapeutics own 15.3% of the company. Learn More about insider trades at Arcturus Therapeutics.
Information on this page was last updated on 10/15/2024.

Pad Chivukula Insider Trading History at Arcturus Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/15/2024	Sell	12,000	$20.76	$249,120.00	435,334
6/5/2024	Sell	114	$45.00	$5,130.00	447,334
6/3/2024	Sell	26,000	$40.01	$1,040,260.00	447,448
3/25/2024	Sell	17,435	$35.02	$610,573.70	473,448
3/19/2024	Sell	8,565	$35.01	$299,860.65	490,883
11/1/2023	Sell	5,000	$18.72	$93,600.00	499,448
10/2/2023	Sell	5,000	$25.61	$128,050.00	504,448
9/1/2023	Sell	5,000	$31.45	$157,250.00	509,448
7/14/2023	Sell	25,000	$35.01	$875,250.00	519,448
7/3/2023	Sell	5,000	$28.75	$143,750.00	544,448
5/10/2023	Sell	17,075	$30.00	$512,250.00	562,373
5/1/2023	Sell	5,000	$25.93	$129,650.00	579,448
4/3/2023	Sell	5,000	$25.38	$126,900.00	584,448
3/6/2023	Sell	5,000	$16.07	$80,350.00	589,448
1/4/2022	Sell	8,100	$40.00	$324,000.00
12/16/2021	Sell	3,633	$40.00	$145,320.00
12/8/2021	Sell	6,367	$40.00	$254,680.00
11/1/2021	Sell	10,000	$44.41	$444,100.00
10/1/2021	Sell	10,000	$44.36	$443,600.00
9/1/2021	Sell	10,000	$55.86	$558,600.00
8/3/2021	Sell	10,000	$40.07	$400,700.00
1/4/2021	Sell	10,000	$46.40	$464,000.00
11/2/2020	Sell	10,000	$55.28	$552,800.00
10/1/2020	Sell	10,000	$42.83	$428,300.00
9/3/2020	Sell	10,000	$45.16	$451,600.00

Pad Chivukula Buying and Selling Activity at Arcturus Therapeutics

Arcturus Therapeutics Company Overview

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Today's Range

Now: $16.02

$14.93

$18.00

50 Day Range

MA: $20.54

$16.02

$25.48

2 Week Range

Now: $16.02

$14.93

$45.00

Volume

1,208,668 shs

Average Volume

470,449 shs

Market Capitalization

$433.98 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.64

[Urgent] Starlink Set For The Largest IPO In History?

From Paradigm Press | Ad